Because of the manufacturer’s decision, Numan may need to raise prices. We’ll let you know about any changes in advance.
What you need to know
From 1st September, the manufacturer of Mounjaro will be increasing the wholesale price by 170%. We know this change may feel concerning, but rest assured, Numan will not be increasing the price of Mounjaro to this extent. Patient care remains our top priority and we’re here to provide guidance and support every step of the way.
The difference between Mounjaro and Wegovy
If you feel your treatment isn’t quite right, our clinicians can assess your case and help you switch to a suitable alternative. Below is a summary of key differences between the GLP-1 medications.
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Mechanism of action | Mimics the actions of GIP and GLP-1, hormones that help regulate appetite and blood sugar levels. | Mimics the action of GLP-1, a hormone that helps regulate appetite. |
| Condition treated | Obesity | Obesity with added cardioprotection |
| Achievable weight loss, according to research | Up to 22.5%¹ | Up to 18%² |
What to do if you want to stay on Mounjaro
While there are other effective and lower-cost treatments, such as Wegovy, you may prefer to continue with Mounjaro. If that’s the case, you still have several options:
If prices increase, you can continue your treatment and pay the new price. If this is your preference, you do not need to do anything and the new price will be updated on any subscription in place after the 1st September.
If a lower dose works well for you, you can remain on that dose, or reduce your maintenance dose, so you’re paying less.
If you decide you’d prefer a more cost-effective solution, you can easily switch to Wegovy following clinical approval.
How to switch to Wegovy
Wegovy is another proven treatment for weight loss. If you’d like to switch, here’s how.
Step one
Submit a request in the app, or complete the online form if you’re new to Numan.
Step two
A clinician will assess your medical background and preferences to determine if Wegovy is appropriate.
Step three
Once approved, your treatment will be delivered along with clear guidance on transitioning from your current medication.
Latest Wegovy research
Since its UK launch in 2023, ongoing research into Wegovy has led to new developments. In 2024, it received approval for use in reducing the risk of cardiovascular events in people with cardiovascular disease.
On top of this, new trial data from June 2025 suggests higher doses of Wegovy can deliver even greater weight loss results.
The Numan Programme
Numan’s Weight Loss Programme pairs clinically-proven medication with one-to-one health coaching. We reject outdated diet culture and patient blame, focusing on modern, effective solutions. With the programme, you’ll receive:
Ongoing clinical care whenever it’s needed
One-to-one support from a health coach to navigate challenges and celebrate wins
Evidence-based guidance to help you understand your body and protect your health
Support when you need it
If you’re still concerned about the ongoing changes, don’t hesitate to reach out to our Customer Care Team. We’re here to help, answer your questions, and guide you through any concerns every step of the way.
FAQS
Your questions answered
KNOWLEDGE
Learn more about our weight loss treatments
/ "Eva")
References
1 Ard J, Lee CJ, Gudzune K, Addison B, Lingvay I, Cao D, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-Diabetes, obesity & metabolism. 2025;27(9): 5064–5071.
2 Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine. 2024;30(7): 2049–2057.
Start your treatment journey
Answer a few simple questions to get the treatment you need.